The changing landscape for patients with relapsed/refractory acute myeloid leukaemia

20216 citationsReview

Authors

Felicetto Ferrara · Fatebenefratelli Hospital

Abstract

The recent approval of new drugs for R/R is transforming the paradigm of care we have relied on for the past 50 years. Ongoing clinical trials will tell us how bright is the future for R/R AML patients.

Topics & Keywords

Acute Myeloid Leukemia Research Hematopoietic Stem Cell Transplantation Multiple Myeloma Research and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Current Opinion in Oncology

Volume 33, Issue 6, pp. 635-641

DOI: 10.1097/cco.0000000000000780

Field-Weighted Citation Impact: 0.73